Forbion Capital Partners, a Naarden, Netherlands-based venture capital firm focused on investing in life sciences companies, closed both FCF I Co-Invest Fund and of FCF II, raising a total of over €190m ($240m).
Forbion’s €54m Co-Invest Fund invests alongside the existing FCF I in late-stage FCF I portfolio companies. The vehicle has already committed funds to five companies, including Circulite, Pathway Medical, AMT Holding, Biovex and Xention.
FCF II, similarly to its predecessor fund FCF I, focuses on private companies developing novel drugs, medical devices and diagnostics for high- or even unmet medical needs. Following the first close, investments have already been made in Niti, arGEN-X, Exosome, Promedior and Cardoz.
Forbion, which invests the majority of the fund in Europe and the remainder in North America and Israel, typically leads the syndicates it forms. The firm recently expanded in Europe by opening an office in Munich and by hiring Dr. Holger Reithinger (formerly with Global Life Sciences Ventures and 3i) in April of this year.
Among its limited partners, Forbion has included the EIF (also through their ERP-EIF and LfA-EIF facilities), US and EU pension funds, major insurance companies and leading European family offices.